TOKENPOST
1 min read
Add as a preferred source on Google

United Therapeutics Acquires Pfizer Royalty Interest Tied to Ralinepag

The deal involves ralinepag, an experimental lung disease therapy, and was disclosed with the company’s third-quarter 2026 results.

By John Kim
Published
An unmarked glass vial rests on a steel laboratory tray / TokenPost.ai
An unmarked glass vial rests on a steel laboratory tray / TokenPost.ai

United Therapeutics acquired Pfizer’s royalty interest linked to ralinepag, an experimental lung disease therapy, as it disclosed the deal alongside its third-quarter 2026 results Wednesday.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…